Updated analysis of survival data from Phase III IMbrave150 study evaluating atezolizumab and bevacizumab compared to sorafenib in people with unresectable hepatocellular carcinoma

Updated analysis conducted after median follow-up of 15.6 months found combination regimen reduced risk of death by 34%, with a median overall survival of 19.2 months vs. 13.4 months for sorafenib in people with unresectable tumour who have not received prior systemic therapy.

Source:

PharmaTimes